Optimal timing for salvage surgery after definitive radiotherapy in hypopharyngeal cancer

Use of radiotherapy combined with chemotherapy is increasing in hypopharyngeal cancer. However, many show residual tumor after radiotherapy. Timing for treatment evaluation and salvage therapy is essential. However, optimal timing for salvage surgery has not been suggested. In this study, we tried t...

Full description

Saved in:
Bibliographic Details
Published inRadiation oncology journal Vol. 36; no. 3; pp. 192 - 199
Main Authors Chun, Seok-Joo, Keam, Bhumsuk, Heo, Dae Seog, Kim, Kwang Hyun, Sung, Myung-Whun, Chung, Eun-Jae, Kim, Ji-hoon, Jung, Kyeong Cheon, Kim, Jin Ho, Wu, Hong-Gyun
Format Journal Article
LanguageEnglish
Published Korea (South) The Korean Society for Radiation Oncology 01.09.2018
대한방사선종양학회
Subjects
Online AccessGet full text
ISSN2234-1900
2234-3156
2234-3164
DOI10.3857/roj.2018.00311

Cover

Loading…
Abstract Use of radiotherapy combined with chemotherapy is increasing in hypopharyngeal cancer. However, many show residual tumor after radiotherapy. Timing for treatment evaluation and salvage therapy is essential. However, optimal timing for salvage surgery has not been suggested. In this study, we tried to evaluate optimal timing for salvage surgery. Patients who were diagnosed with hypopharyngeal squamous cell carcinoma between 2006 and 2015 were retrospectively analyzed. All patients received definitive radiotherapy with or without chemotherapy. Response of all treated patients were analyzed at 1, 3, and 6 months after radiotherapy. Any patients with progression before 6 months were excluded. A total of 54 patients were analyzed. Complete remission (CR) rates at 1 month (CR1), 3 months (CR3) and 6 months (CR6) were 66.7%, 81.5%, and 90.7%, respectively. Non-CR at 1 month (NCR1), 3 months (NCR3), and 6 months (NCR6) showed poor locoregional recurrence-free survival rates (1-year rates of 63.7%, 66.7%, and 0.0%, respectively) compared to CR1, CR3, and CR6 (1-year rates 94.3%, 88.0%, and 91.5%, respectively). Particularly significant differences were seen between CR6 and NCR6 (p < 0.001). Of 10 patients with NCR3, 5 showed CR at 6 months (NCR3/CR6). There was no statistical difference in locoregional recurrence-free survival between CR3 and NCR3/CR6 group (p = 0.990). Our data suggest half of patients who did not show CR at 3 months eventually achieved CR at 6 months. Waiting until 6 months after radiotherapy may be appropriate for avoiding additional salvage therapy.
AbstractList Use of radiotherapy combined with chemotherapy is increasing in hypopharyngeal cancer. However, many show residual tumor after radiotherapy. Timing for treatment evaluation and salvage therapy is essential. However, optimal timing for salvage surgery has not been suggested. In this study, we tried to evaluate optimal timing for salvage surgery.PURPOSEUse of radiotherapy combined with chemotherapy is increasing in hypopharyngeal cancer. However, many show residual tumor after radiotherapy. Timing for treatment evaluation and salvage therapy is essential. However, optimal timing for salvage surgery has not been suggested. In this study, we tried to evaluate optimal timing for salvage surgery.Patients who were diagnosed with hypopharyngeal squamous cell carcinoma between 2006 and 2015 were retrospectively analyzed. All patients received definitive radiotherapy with or without chemotherapy. Response of all treated patients were analyzed at 1, 3, and 6 months after radiotherapy. Any patients with progression before 6 months were excluded.METHODS AND MATERIALSPatients who were diagnosed with hypopharyngeal squamous cell carcinoma between 2006 and 2015 were retrospectively analyzed. All patients received definitive radiotherapy with or without chemotherapy. Response of all treated patients were analyzed at 1, 3, and 6 months after radiotherapy. Any patients with progression before 6 months were excluded.A total of 54 patients were analyzed. Complete remission (CR) rates at 1 month (CR1), 3 months (CR3) and 6 months (CR6) were 66.7%, 81.5%, and 90.7%, respectively. Non-CR at 1 month (NCR1), 3 months (NCR3), and 6 months (NCR6) showed poor locoregional recurrence-free survival rates (1-year rates of 63.7%, 66.7%, and 0.0%, respectively) compared to CR1, CR3, and CR6 (1-year rates 94.3%, 88.0%, and 91.5%, respectively). Particularly significant differences were seen between CR6 and NCR6 (p < 0.001). Of 10 patients with NCR3, 5 showed CR at 6 months (NCR3/CR6). There was no statistical difference in locoregional recurrence-free survival between CR3 and NCR3/CR6 group (p = 0.990).RESULTSA total of 54 patients were analyzed. Complete remission (CR) rates at 1 month (CR1), 3 months (CR3) and 6 months (CR6) were 66.7%, 81.5%, and 90.7%, respectively. Non-CR at 1 month (NCR1), 3 months (NCR3), and 6 months (NCR6) showed poor locoregional recurrence-free survival rates (1-year rates of 63.7%, 66.7%, and 0.0%, respectively) compared to CR1, CR3, and CR6 (1-year rates 94.3%, 88.0%, and 91.5%, respectively). Particularly significant differences were seen between CR6 and NCR6 (p < 0.001). Of 10 patients with NCR3, 5 showed CR at 6 months (NCR3/CR6). There was no statistical difference in locoregional recurrence-free survival between CR3 and NCR3/CR6 group (p = 0.990).Our data suggest half of patients who did not show CR at 3 months eventually achieved CR at 6 months. Waiting until 6 months after radiotherapy may be appropriate for avoiding additional salvage therapy.CONCLUSIONOur data suggest half of patients who did not show CR at 3 months eventually achieved CR at 6 months. Waiting until 6 months after radiotherapy may be appropriate for avoiding additional salvage therapy.
Use of radiotherapy combined with chemotherapy is increasing in hypopharyngeal cancer. However, many show residual tumor after radiotherapy. Timing for treatment evaluation and salvage therapy is essential. However, optimal timing for salvage surgery has not been suggested. In this study, we tried to evaluate optimal timing for salvage surgery. Patients who were diagnosed with hypopharyngeal squamous cell carcinoma between 2006 and 2015 were retrospectively analyzed. All patients received definitive radiotherapy with or without chemotherapy. Response of all treated patients were analyzed at 1, 3, and 6 months after radiotherapy. Any patients with progression before 6 months were excluded. A total of 54 patients were analyzed. Complete remission (CR) rates at 1 month (CR1), 3 months (CR3) and 6 months (CR6) were 66.7%, 81.5%, and 90.7%, respectively. Non-CR at 1 month (NCR1), 3 months (NCR3), and 6 months (NCR6) showed poor locoregional recurrence-free survival rates (1-year rates of 63.7%, 66.7%, and 0.0%, respectively) compared to CR1, CR3, and CR6 (1-year rates 94.3%, 88.0%, and 91.5%, respectively). Particularly significant differences were seen between CR6 and NCR6 (p < 0.001). Of 10 patients with NCR3, 5 showed CR at 6 months (NCR3/CR6). There was no statistical difference in locoregional recurrence-free survival between CR3 and NCR3/CR6 group (p = 0.990). Our data suggest half of patients who did not show CR at 3 months eventually achieved CR at 6 months. Waiting until 6 months after radiotherapy may be appropriate for avoiding additional salvage therapy.
Purpose: Use of radiotherapy combined with chemotherapy is increasing in hypopharyngeal cancer. However, many show residual tumor after radiotherapy. Timing for treatment evaluation and salvage therapy is essential. However, optimal timing for salvage surgery has not been suggested. In this study, we tried to evaluate optimal timing for salvage surgery. Methods and Materials: Patients who were diagnosed with hypopharyngeal squamous cell carcinoma between 2006 and 2015 were retrospectively analyzed. All patients received definitive radiotherapy with or without chemotherapy. Response of all treated patients were analyzed at 1, 3, and 6 months after radiotherapy. Any patients with progression before 6 months were excluded. Results: A total of 54 patients were analyzed. Complete remission (CR) rates at 1 month (CR1), 3 months (CR3) and 6 months (CR6) were 66.7%, 81.5%, and 90.7%, respectively. Non-CR at 1 month (NCR1), 3 months (NCR3), and 6 months (NCR6) showed poor locoregional recurrence-free survival rates (1-year rates of 63.7%, 66.7%, and 0.0%, respectively) compared to CR1, CR3, and CR6 (1- year rates 94.3%, 88.0%, and 91.5%, respectively). Particularly significant differences were seen between CR6 and NCR6 (p < 0.001). Of 10 patients with NCR3, 5 showed CR at 6 months (NCR3/CR6). There was no statistical difference in locoregional recurrence-free survival between CR3 and NCR3/CR6 group (p = 0.990). Conclusion: Our data suggest half of patients who did not show CR at 3 months eventually achieved CR at 6 months. Waiting until 6 months after radiotherapy may be appropriate for avoiding additional salvage therapy. KCI Citation Count: 0
Author Jung, Kyeong Cheon
Kim, Jin Ho
Wu, Hong-Gyun
Sung, Myung-Whun
Keam, Bhumsuk
Kim, Ji-hoon
Kim, Kwang Hyun
Chung, Eun-Jae
Chun, Seok-Joo
Heo, Dae Seog
Author_xml – sequence: 1
  givenname: Seok-Joo
  surname: Chun
  fullname: Chun, Seok-Joo
– sequence: 2
  givenname: Bhumsuk
  surname: Keam
  fullname: Keam, Bhumsuk
– sequence: 3
  givenname: Dae Seog
  surname: Heo
  fullname: Heo, Dae Seog
– sequence: 4
  givenname: Kwang Hyun
  surname: Kim
  fullname: Kim, Kwang Hyun
– sequence: 5
  givenname: Myung-Whun
  surname: Sung
  fullname: Sung, Myung-Whun
– sequence: 6
  givenname: Eun-Jae
  surname: Chung
  fullname: Chung, Eun-Jae
– sequence: 7
  givenname: Ji-hoon
  surname: Kim
  fullname: Kim, Ji-hoon
– sequence: 8
  givenname: Kyeong Cheon
  surname: Jung
  fullname: Jung, Kyeong Cheon
– sequence: 9
  givenname: Jin Ho
  surname: Kim
  fullname: Kim, Jin Ho
– sequence: 10
  givenname: Hong-Gyun
  surname: Wu
  fullname: Wu, Hong-Gyun
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30309210$$D View this record in MEDLINE/PubMed
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002389021$$DAccess content in National Research Foundation of Korea (NRF)
BookMark eNp1UU1r3DAQFSWlSbe59lh0bA-71Yct2ZdCCGkbCARKeuhJyPLIq8QruZJ2wf--2o-GtlAxaAb03pvRvNfozAcPCL2lZMWbWn6M4XHFCG1WhHBKX6ALxni15LQWZ6eatoSco8uUHkk5gtRCkFfonBNOWkbJBfpxP2W30SMut_MDtiHipMedHgCnbRwgzljbDBH3YJ132e0AR927kNcQ9TRj5_F6nsK01nH2AxQpo72B-Aa9tHpMcHnKC_T9883D9dfl3f2X2-uru6WpWJWXsrEapKVVV0uou0Z2rJKMtbrVRui20rUgjbG15LShFhiHvpU9FZ01tezLJxfow1HXR6uejFNBu0MegnqK6urbw63iUgheYoE-HbHTtttAb8DnqEc1xbKCOB-Yf794ty46OyUYE7SiReD9SSCGn1tIWW1cMjCO2kPYJsUobVtGWtkU6Ls_ez03-b37AlgdASaGlCLYZwglau-vKv6qvb_q4G8hVP8QjMs6u7Cf1Y3_o_0C3Xuq2w
CitedBy_id crossref_primary_10_1186_s12885_020_06793_6
crossref_primary_10_1007_s12070_020_01806_z
Cites_doi 10.1016/j.ijrobp.2010.11.072
10.1001/archotol.126.12.1473
10.1007/s00405-010-1274-3
10.1002/lary.24915
10.1001/archotol.130.7.875
10.1016/j.radonc.2009.04.014
10.2214/ajr.184.2.01840579
10.1002/hed.10310
10.1002/hed.21613
10.1056/NEJMoa1514493
10.1016/j.ijrobp.2013.08.049
10.1093/annonc/mds065
10.1002/hed.20978
10.1007/s00405-009-1028-2
10.1097/MLG.0b013e31815a9ed3
10.1016/j.ejca.2008.10.026
ContentType Journal Article
Copyright Copyright © 2018. The Korean Society for Radiation Oncology 2018
Copyright_xml – notice: Copyright © 2018. The Korean Society for Radiation Oncology 2018
DBID AAYXX
CITATION
NPM
7X8
5PM
ACYCR
DOI 10.3857/roj.2018.00311
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
Korean Citation Index
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
PubMed

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
EISSN 2234-3156
2234-3164
EndPage 199
ExternalDocumentID oai_kci_go_kr_ARTI_3766366
PMC6226141
30309210
10_3857_roj_2018_00311
Genre Journal Article
GrantInformation_xml – fundername: Ministry of Health and Welfare
  grantid: 1631200
– fundername: Ministry of Education, Science and Technology
  grantid: 50595-2018
GroupedDBID 5-W
8JR
8XY
9ZL
AAKDD
AAYXX
ABDBF
ACUHS
ADBBV
ADRAZ
AEGXH
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
CITATION
DIK
EF.
GX1
HYE
KQ8
M48
OK1
PGMZT
RPM
KVFHK
NPM
7X8
5PM
.UV
ACYCR
ID FETCH-LOGICAL-c424t-78fae7f14b57e5b87b247229a9ac6a94a5608cf573181fe23ed97d16bfc57d223
IEDL.DBID M48
ISSN 2234-1900
IngestDate Tue Nov 21 21:37:11 EST 2023
Thu Aug 21 14:01:30 EDT 2025
Fri Jul 11 12:36:01 EDT 2025
Wed Feb 19 02:42:19 EST 2025
Tue Jul 01 01:32:54 EDT 2025
Thu Apr 24 22:59:56 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords Hypopharynx
Radiotherapy
Neoplasms
Language English
License This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c424t-78fae7f14b57e5b87b247229a9ac6a94a5608cf573181fe23ed97d16bfc57d223
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3857/roj.2018.00311
PMID 30309210
PQID 2119920978
PQPubID 23479
PageCount 8
ParticipantIDs nrf_kci_oai_kci_go_kr_ARTI_3766366
pubmedcentral_primary_oai_pubmedcentral_nih_gov_6226141
proquest_miscellaneous_2119920978
pubmed_primary_30309210
crossref_primary_10_3857_roj_2018_00311
crossref_citationtrail_10_3857_roj_2018_00311
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2018-09-01
PublicationDateYYYYMMDD 2018-09-01
PublicationDate_xml – month: 09
  year: 2018
  text: 2018-09-01
  day: 01
PublicationDecade 2010
PublicationPlace Korea (South)
PublicationPlace_xml – name: Korea (South)
PublicationTitle Radiation oncology journal
PublicationTitleAlternate Radiat Oncol J
PublicationYear 2018
Publisher The Korean Society for Radiation Oncology
대한방사선종양학회
Publisher_xml – name: The Korean Society for Radiation Oncology
– name: 대한방사선종양학회
References ref13
ref12
ref15
ref14
ref11
ref10
ref2
ref1
ref17
ref16
ref7
(ref8) 1991
ref9
ref4
ref3
ref6
ref5
References_xml – ident: ref10
  doi: 10.1016/j.ijrobp.2010.11.072
– ident: ref15
  doi: 10.1001/archotol.126.12.1473
– ident: ref16
  doi: 10.1007/s00405-010-1274-3
– ident: ref3
  doi: 10.1002/lary.24915
– ident: ref14
  doi: 10.1001/archotol.130.7.875
– ident: ref2
  doi: 10.1016/j.radonc.2009.04.014
– ident: ref12
  doi: 10.2214/ajr.184.2.01840579
– ident: ref17
  doi: 10.1002/hed.10310
– ident: ref5
  doi: 10.1002/hed.21613
– ident: ref11
  doi: 10.1056/NEJMoa1514493
– ident: ref6
  doi: 10.1016/j.ijrobp.2013.08.049
– ident: ref1
  doi: 10.1093/annonc/mds065
– ident: ref9
  doi: 10.1002/hed.20978
– ident: ref4
  doi: 10.1007/s00405-009-1028-2
– ident: ref13
  doi: 10.1097/MLG.0b013e31815a9ed3
– ident: ref7
  doi: 10.1016/j.ejca.2008.10.026
– start-page: 1685
  volume-title: Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer
  year: 1991
  ident: ref8
SSID ssj0000605660
Score 2.0816548
Snippet Use of radiotherapy combined with chemotherapy is increasing in hypopharyngeal cancer. However, many show residual tumor after radiotherapy. Timing for...
Purpose: Use of radiotherapy combined with chemotherapy is increasing in hypopharyngeal cancer. However, many show residual tumor after radiotherapy. Timing...
SourceID nrf
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 192
SubjectTerms Original
방사선과학
Title Optimal timing for salvage surgery after definitive radiotherapy in hypopharyngeal cancer
URI https://www.ncbi.nlm.nih.gov/pubmed/30309210
https://www.proquest.com/docview/2119920978
https://pubmed.ncbi.nlm.nih.gov/PMC6226141
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002389021
Volume 36
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Radiation oncology journal , 2018, 36(3), , pp.192-199
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV1LS8NAEF60gngRxVd9lFUET5Em2ewmBxERpQrqxYKelk2y20ZrUtMq5t87k6S1Sj0FkiUhM5OZb7Iz3xByDGai2iHyaSsNCQqPfSv0BcMqi1Cb2CCGx2qLe97pstsn7-mn_qkW4GhuaofzpLr54PTrvTiHD_4MM04fEvo8e8EaLSyKdLHNdwmiEkcLv6uhfuWVIdSXTcMQEJkFcbBdcTjOucUKWXZx68HBvtqZcLWY5mYeEv1bUDkToa7XyGoNLelFZQvrZEGnG-T5AXzCG5we4_iuHgWMSkdq8AluhI6qlmhazgmnsTZJVUlEcxUndWdWQZOU9othNuyrvEh7gCtphJaSb5Lu9dXjZceqxylYEXPY2BK-UVqA9ENPaA80EjrIFBmoQEVcBUwB-PEj4wnQn2204-o4ELHNQxN5IgapbZFGmqV6h1DhOSCfKGBt47PQKL_NA1uB81O2AshmN4k1kZqMaq5xHHkxkJBzoMAlCFyiwEtuUlh_Ml0_rFg2_l15BEqQr1EikRgbj71MvuYS4P-NBG_JXc6b5HCiIwlfC26BqFRnHyOJfHaBg70rTbJd6Wz6wInKm0T80uZ0AT7w95U06ZeM3BxArM3s3X_vuUdW8B2q4rR90hjnH_oA0Mw4bJVm2ip_M30D8lPxYw
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Optimal+timing+for+salvage+surgery+after+definitive+radiotherapy+in+hypopharyngeal+cancer&rft.jtitle=Radiation+oncology+journal&rft.au=Chun%2C+Seok-Joo&rft.au=Keam%2C+Bhumsuk&rft.au=Heo%2C+Dae+Seog&rft.au=Kim%2C+Kwang+Hyun&rft.date=2018-09-01&rft.issn=2234-1900&rft.volume=36&rft.issue=3&rft.spage=192&rft_id=info:doi/10.3857%2Froj.2018.00311&rft_id=info%3Apmid%2F30309210&rft.externalDocID=30309210
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2234-1900&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2234-1900&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2234-1900&client=summon